A recent analysis of 141 eligible neoadjuvant and adjuvant breast cancer trials found that only 4 (2.8%) included post-intervention AMH data, a surrogate marker of ovarian reserve.79 These findings highlight the significant gap in knowledge in this area, which demands the need for intentional trial design to address fertility outcomes in YWBC (see Table 1). The gene discussed is AMH; the disease is breast carcinoma.